Dana Investment Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.06M Buy
8,107
+99
+1% +$47.5K 0.11% 226
2026
Q1
$3.94M Sell
8,008
-1,238
-13% -$672K 0.12% 210
2025
Q4
$5.36M Sell
9,246
-211
-2% -$119K 0.16% 158
2025
Q3
$4.59M Buy
9,457
+1,884
+25% +$877K 0.13% 174
2025
Q2
$3.07M Sell
7,573
-168
-2% -$70.2K 0.1% 220
2025
Q1
$3.85M Buy
7,741
+31
+0.4% +$16.8K 0.14% 184
2024
Q4
$4.01M Sell
7,710
-125
-2% -$68.7K 0.13% 192
2024
Q3
$4.85M Buy
7,835
+144
+2% +$85.2K 0.16% 168
2024
Q2
$4.25M Buy
7,691
+19
+0.2% +$10.9K 0.14% 183
2024
Q1
$4.46M Sell
7,672
-1,200
-14% -$673K 0.15% 182
2023
Q4
$4.71M Sell
8,872
-326
-4% -$158K 0.23% 99
2023
Q3
$4.66M Buy
9,198
+4,929
+115% +$2.63M 0.24% 96
2023
Q2
$2.23M Buy
4,269
+6
+0.1% +$3.24K 0.11% 132
2023
Q1
$2.46M Sell
4,263
-9,001
-68% -$5.07M 0.12% 123
2022
Q4
$7.3M Buy
13,264
+1,820
+16% +$964K 0.38% 71
2022
Q3
$5.8M Buy
11,444
+3,747
+49% +$2.1M 0.33% 79
2022
Q2
$4.18M Sell
7,697
-2,689
-26% -$1.48M 0.21% 93
2022
Q1
$6.13M Sell
10,386
-846
-8% -$486K 0.28% 76
2021
Q4
$7.49M Sell
11,232
-987
-8% -$616K 0.32% 79
2021
Q3
$6.98M Sell
12,219
-4,332
-26% -$2.38M 0.32% 75
2021
Q2
$8.35M Sell
16,551
-1,212
-7% -$572K 0.37% 76
2021
Q1
$8.11M Sell
17,763
-43,341
-71% -$20.7M 0.37% 74
2020
Q4
$28.5M Sell
61,104
-1,530
-2% -$717K 1.41% 17
2020
Q3
$27.7M Sell
62,634
-5,006
-7% -$2.07M 1.51% 15
2020
Q2
$24.5M Sell
67,640
-10,443
-13% -$3.5M 1.33% 24
2020
Q1
$22.1M Sell
78,083
-23,990
-24% -$7.56M 1.35% 32
2019
Q4
$33.2M Buy
102,073
+2,103
+2% +$638K 1.59% 16
2019
Q3
$29.1M Buy
99,970
+4,038
+4% +$1.16M 1.48% 28
2019
Q2
$28.2M Buy
95,932
+78,296
+444% +$21.6M 1.39% 27
2019
Q1
$4.83M Sell
17,636
-3,419
-16% -$851K 0.23% 87
2018
Q4
$4.71M Sell
21,055
-1,306
-6% -$306K 0.24% 88
2018
Q3
$5.46M Sell
22,361
-536
-2% -$123K 0.22% 91
2018
Q2
$4.74M Sell
22,897
-333
-1% -$70.7K 0.21% 96
2018
Q1
$4.8M Buy
23,230
+21,623
+1,346% +$4.54M 0.22% 96
2017
Q4
$305K Buy
1,607
+531
+49% +$102K 0.01% 246
2017
Q3
$204K Buy
+1,076
New +$195K 0.01% 260
2017
Q2
Sell
-3,702
Closed -$569K 300
2017
Q1
$569K Sell
3,702
-497
-12% -$76K 0.03% 230
2016
Q4
$592K Buy
+4,199
New +$619K 0.03% 225
2016
Q3
Sell
-3,618
Closed -$535K 296
2016
Q2
$535K Buy
3,618
+902
+33% +$133K 0.02% 219
2016
Q1
$385K Buy
+2,716
New +$364K 0.02% 231
2015
Q2
Sell
-21,899
Closed -$2.94M 281
2015
Q1
$2.94M Sell
21,899
-3,634
-14% -$468K 0.14% 115
2014
Q4
$3.2M Buy
25,533
+4,247
+20% +$516K 0.13% 111
2014
Q3
$2.59M Sell
21,286
-9,229
-30% -$1.12M 0.15% 120
2014
Q2
$3.6M Buy
30,515
+8,120
+36% +$956K 0.21% 92
2014
Q1
$2.69M Sell
22,395
-654
-3% -$77.8K 0.17% 106
2013
Q4
$2.57M Sell
23,049
-164,025
-88% -$16.3M 0.16% 109
2013
Q3
$17.2M Sell
187,074
-20,206
-10% -$1.83M 1.24% 36
2013
Q2
$17.5M Buy
+207,280
New +$17.3M 1.33% 27

Other funds holding TMO

Dana Investment Advisors's TMO Position: Q2 2026 in Review

Dana Investment Advisors increased its Thermo Fisher Scientific (TMO) stake by 1.2% in Q2 2026, buying an estimated $47.5K and bringing the position to 8,107 shares worth $4.06M. The position accounts for 0.11% of the portfolio, ranked #226.

Dana Investment Advisors first reported a position in TMO in Q2 2013 and has held it in 48 quarters since. The position peaked at $33.2M in Q4 2019. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Dana Investment Advisors held 8,107 shares of Thermo Fisher Scientific worth $4.06M as of Q2 2026.
  • Dana Investment Advisors bought 99 Thermo Fisher Scientific shares in Q2 2026, an estimated $47.5K.
  • Thermo Fisher Scientific made up 0.11% of Dana Investment Advisors's portfolio in Q2 2026, its #226 holding.
  • Dana Investment Advisors first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 48 quarters since.
  • Dana Investment Advisors's Thermo Fisher Scientific position peaked at $33.2M in Q4 2019.
  • 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Dana Investment Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.